Orthofix Medical (OFIX) News Today

Orthofix Medical Inc. (NASDAQ: OFIX) shares were under pressure despite a better-than-expected second quarter and an above-consensus full-year revenue outlook. Investors appear focused on the company’s continuing GAAP losses, weak profitability and uncertainty around the quality and sustainability of the earnings improvement.

• Positive Sentiment: Orthofix reported second-quarter revenue of approximately $210.9 million, exceeding analysts’ $209.3 million estimate. Adjusted earnings were $0.07 per share, ahead of the $0.03-per-share loss expected by Zacks, while the company’s reported GAAP loss of $0.39 per share was slightly better than the $0.41 consensus loss. Orthofix Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The company forecast 2026 net sales of $845 million to $855 million, above the roughly $841 million analyst consensus. Management said the outlook is supported in part by a $15 million European MDR inventory order, providing a near-term sales benefit. Orthofix 2026 Net Sales Forecast
• Neutral Sentiment: The earnings call highlighted the revenue outlook and quarterly performance, but the company did not provide a clearly specified full-year EPS forecast in the available guidance update. Orthofix Q2 2026 Earnings Call Summary
• Negative Sentiment: Orthofix remains unprofitable on a GAAP basis, with a negative net margin and negative return on equity. The company is also expected to post a sizable full-year loss, which may outweigh the quarterly earnings and revenue beats for investors seeking evidence of durable profitability. Orthofix Earnings Report